metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
mML - L2 - all population metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - all population
versus placebo plus SoC
	ipilimumab plus SoC
	CA184-024, 2011 N Engl J Med 2011;364:2517-26 J Clin Oncol 2015;33:1191-6 NCT00324155	RCT	mML - L2 - all population	ipilimumab plus dacarbazine	dacarbazine plus placebo	patients with previously untreated metastatic melanoma, (stage III (unresectable) or stage IV melanoma) with measurable lesions; all patients received dacarbazine.	250 / 252	low	conclusif	demonstrated 28 % decrease in deaths (OS) (PE) demonstrated 24 % decrease in progression or deaths (PFS) (PE) suggested 31 % decrease in deaths (OS) (extension)